Government-Owned Inventions; Availability for Licensing, 52802-52804 [E6-14753]
Download as PDF
<![CDATA[
52802
Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
rwilkins on PROD1PC63 with NOTICES
Differential Expression of Molecules
Associated With Intra-Cerebral
Hemorrhage
Description of Technology: Stroke
affects 15 million people worldwide
each year, and is the number three
leading cause of morbidity in the United
States. Although most forms of stroke
are ischemic in nature, approximately
10–15% of strokes are hemorrhagic. At
present, clinical applications for
distinguishing between these two forms
of stroke do not exist.
The present invention describes a
highly predictive, cost-effective
diagnostic assay capable of detecting
whether an individual has suffered from
an intracerebral hemorrhagic stroke and
the likelihood of neurological recovery.
It comprises a rapid screening device for
measuring differential expression
patterns of nucleic acid molecules or
proteins of at least four hemorrhagic
stroke-related genes. Accurate
prediction of hemorrhagic stroke will
improve rapid diagnosis and aid in
determining early treatment regimens.
Applications:
1. Gene expression profile assay for
determining hemorrhagic stroke victims.
2. Means of differentiating between
hemorrhagic stroke and ischemic stroke
VerDate Aug<31>2005
18:11 Sep 06, 2006
Jkt 208001
thereby optimizing patient response to
stroke therapies.
Market:
1. Annually, fifteen billion people
suffer from strokes worldwide, and an
estimated 700,000 individuals have
first-time or recurrent strokes each year
in the United States alone.
2. Almost three-fourth of all strokes
occur in individuals over 65 years of
age.
3. In 2006, the projected indirect and
direct costs of stroke are $57.9 billion.
Development Status: This technology
requires clinical validation studies.
Inventors: Alison Baird (NINDS) et al.
Patent Status: U.S. Provisional
Application No. 60/807,027 filed 11 Jul
2006 (HHS Reference No. E–197–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301/435–4521;
sayyidf@mail.nih.gov.
Collaborative Research Opportunity:
NINDS is also seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this assay for
determining hemorrhagic stroke victims.
For additional information, please
contact: Heather Gunas, J.D., M.P.H;
NINDS c/o NCI TTB; 6120 Executive
Blvd., Suite 450, Rockville, MD 20852;
Phone: 301–451–3944; Fax: 301–402–
2117; E-mail: gunash@mail.nih.gov.
Diagnosis and Prognosis of Fabry
Disease by Detecting Neuronal
Apoptosis Inhibitor Protein (NAIP)
Expression
Description of Technology: Fabry
disease is a severe metabolic disorder
that affects the vascular system of
multiple tissues and organs. An
estimated 1 in 40,000 individuals
inherit this rare disease, and suffer from
various complications including stroke,
renal failure, and cardiac arrest. At
present, molecular markers that directly
measure cellular dysfunction to not
exist, thus, prognosis for Fabry disease
therapy can not be assessed.
Available for licensing and
commercial development is a rapid
diagnostic assay to identify individuals
with Fabry disease and an effective
mechanism of evaluating enzyme
replacement therapy. It provides a
quick, inexpensive device for
determining expression patterns of the
neuronal apoptosis inhibitor protein
(NAIP). Peripheral blood white cells of
Fabry disease patients are analyzed for
elevated levels of the marker NAIP,
which is over-expressed in patients
suffering from acute strokes. These
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
elevated levels have been found in
children with Fabry disease and point to
the need for preventive therapies.
Additionally, this test can be routinely
utilized for evaluation of specific and
non-specific therapies that aid in
minimizing the complications
associated with Fabry disease.
Applications:
1. Rapid diagnostic test to identify
person at risk for Fabry disease.
2. Reliable diagnostic test to identify
subject response to Fabry disease
therapy.
Market: Individuals genetically
susceptible to Fabry disease.
Development Status: This technology
requires analytic validation.
Inventors: Raphael Schiffmann
(NINDS) et al.
Related Publications:
1. DF Moore, H Li, N Jeffries, V
Wright, RA Cooper Jr, A Elkahloun, MP
Gelderman, E Zudaire, G Blevins, H Yu,
E Goldin, AE Baird. Using peripheral
blood mononuclear cells to determine a
gene expression profile of acute
ischemic stroke: a pilot investigation.
Circulation. 2005 Jan 18; 111(2):212–
221.
2. Y Okada, H Sakai, E Kohiki, E Suga,
Y Yanagisawa, K Tanaka, S Hadano, H
Osuga, JE Ikeda. A dopamine D4
receptor antagonist attenuates ischemiainduced neuronal cell damage via
upregulation of neuronal apoptosis
inhibitory protein. J Cereb Blood Flow
Metab. 2005 Jul; 25(7):794–806.
3. N Inohara, M Chamaillard, C
˜
McDonald, G Nunez. NOD–LRR
proteins: role in host-microbial
interactions and inflammatory disease.
Annu Rev Biochem. 2005 Jul; 74:355–
383.
Patent Status: U.S. Provisional
Application No. 60/806,295 filed 30 Jun
2006 (HHS Reference No. E–196–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301/435–4521;
sayyidf@mail.nih.gov.
Novel Treatment of Vascular Cognitive
Impairment
Description of Technology: Available
for licensing are methods and
formulations for treating or preventing
Vascular Cognitive Impairment (VCI)
through mucosal administration of Eselectin, an inducible adhesion
molecule on endothelial cells. Vascular
dementia is defined as the loss of
cognitive function resulting from
ischemic, ischemic-hypoxic, or
hemorrhagic brain lesions as a result of
cerebrovascular diseases and pathologic
E:\FR\FM\07SEN1.SGM
07SEN1
Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices
changes. Presently no adequate medical
treatment exists for VCI.
Cerebrovascular disease causes
proinflammatory cytokines such as IL–
1 and TNF to induce the expression of
E-selectin on human endothelium. Eselectin mediates the adhesion of
various leukocytes, including
neutrophils, monocytes, eosinophils,
natural killer cells, and a subset of T
cells to the activated endothelium.
Activation of vascular endothelial cells
by proinflammatory cytokines is
believed to be involved in conversion of
the luminal surface of endothelium from
anticoagulant and anti-inflammatory to
procoagulant and pro-inflammatory.
These vascular changes are thought to
underlie the development of VCI.
Mucosally administered antigens can
inhibit immune responses in an antigen
specific fashion by inducing a subset of
lymphocytes to produce antiinflammatory cytokines in the presence
of the antigen. This type of tolerance has
been termed ‘‘bystander suppression’’.
In an animal model of VCI, intranasal
administered E-selectin suppressed
activation of vessel segments beginning
to express E-selectin and thus prevented
the development of VCI.
Immunosuppression via antigen-specific
modulation of the immune response
(mucosal tolerance) should have no
systemic immunosuppressive effects.
Inventors: John M. Hallenbeck et al.
(NINDS).
Patent Status: U.S. Provisional
Application No. 60/712,359 filed 30
Aug 2005 (HHS Reference No. E–271–
2005/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Norbert Pontzer,
Ph.D., J.D.; 301/435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The NINDS Stroke Branch is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the use of E-selectin for
treatment of VCI. For more information,
please contact: Laurie Arrants, NINDS
Technology Transfer Office, 301–435–
3112; arrantsl@ninds.nih.gov.
rwilkins on PROD1PC63 with NOTICES
Use of LCAT To Reduce Cholesterol
and Prevent Atherosclerosis
Description of Technology: Available
for licensing and commercial
development is a method of decreasing
accumulation of cholesterol in arteries
of humans by administering lecithincholesterol acyltransferase (LCAT). This
method is useful for the therapeutic
treatment of subjects at risk for
developing atherosclerosis.
VerDate Aug<31>2005
19:26 Sep 06, 2006
Jkt 208001
High plasma concentration of HDL
cholesterol is associated with reduced
risk of cardiovascular diseases (such as
ischemic stroke and myocardial
infarction). In contrast, low levels of
HDL are associated with increased risk
of atherosclerotic diseases. The plasma
protein enzyme LCAT plays a critical
role in the metabolism of HDL and it
facilitates the removal of cholesterol
from the body. Individuals with a
mutation in the LCAT gene have low
HDL plasma levels and exhibit an
increased risk for atherosclerosis.
Therefore, upregulation of LCAT
function has been proposed as an HDL–
C increasing therapy, and may have
atheroprotective effects. This invention
provides for several methods of
administering LCAT polypeptide to
decrease cholesterol accumulation in
arteries.
Development Status: Animal data
available.
Inventors: Silvia Santamarina-Fojo,
Jeffrey M. Hoeg, H. Bryan Brewer
(NHLBI).
Relevant Publication: JM Hoeg et al.
Overexpression of lecithin:cholesterol
acyltransferase in transgenic rabbits
prevents diet-induced atherosclerosis.
Proc Natl Acad Sci USA. 1996 Oct
15;93(21):11448–11453.
Patent Status: U.S. Patent No.
6,635,641 issued on 21 Oct 2003 (HHS
Reference No. E–007–1996/0–US–03);
PCT Application No. PCT/US96/18159
filed 09 Sep 1996, which was published
as WO 1997/17434 on 15 May 1997
(HHS Reference No. E–007–1996/0–
PCT–02); Australian Patent No. 728257
issued on 19 Apr 2001; and National
Stage filings in Canada and Europe.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact:
NIHOTT@mail.nih.gov; 301/496–7057.
Devices for Aseptic Lyophilization of
Biological Samples
Description of Technology: Biological
materials are often lyophilized and
stored in small aliquots for long-term
preservation as a means of improving
stability and expanding shelf life. At
present, sterility of solutions cannot be
preserved throughout the lyophilization
process, and reconstituted samples must
be filtered to remove contaminants such
as fungi or bacteria, resulting in
considerable loss of expensive sample
via absorption by the filter. Thus, there
exists a need for a device that eliminates
microbial contamination throughout the
lyophilization process and provides
materials that are ready to use following
lyophilization.
This technology offers a functional
method to prevent microbial
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
52803
contamination during lyophilization
and a simple means to prevent
contamination. It affords a convenient
system for gas venting and exchange
utilizing a microcentrifuge tube fitted
with a cap incorporating a filter
membrane. In a related technology, a
unique, cost-effective multi-well plate
assembly provides for simultaneous
lyophilization of small sample volumes
for high-throughput operations. Thus,
these technologies are well-suited for
researchers concerned about
contamination during the lyophilization
process. Given the spillage often
occurring within centrifugal freezedryers, these technologies are also
useful even when sterility is not needed,
as they prevent contamination from the
often-dirty interiors of laboratory
centrifugal freeze-dryers, as well as
cross-contamination between samples
undergoing lyophilization. In addition,
by extending shelf-lives, these
technologies enable researchers to
purchase expensive biomolecules and
pharmaceuticals in money-saving bulk
quantities. Furthermore, these
technologies permit cells to be grown
and stored axenically, in small
quantities, with or without
lyophilization.
Applications:
1. Maximizes the shelf-lives of
expensive biomolecules and
pharmaceuticals.
2. Makes practical the bulk purchase
of expensive biomolecules and
pharmaceuticals by extending shelflives.
3. Makes possible the axenic storage
of cells via aseptic freeze-drying.
4. Makes possible the production and
use of small, sterile aliquots of precious
materials by eliminating unnecessary
filtration steps.
5. Makes possible the sterile growth of
cells in small volumes.
Market:
1. Researchers worldwide who utilize
sterile, labile compounds.
2. Researchers who utilize microbial,
plant, or animal cell cultures.
Development Status: Development is
complete and invention has been
successfully tested.
Inventors: Geoffrey Kidd (NCI).
Patent Status: U.S. Patent 5,958,778
issued 28 Sep 1999 (HHS Reference No.
E–015–1995/2–US–01); U.S. Patent
6,503,455 issued 07 Jan 2003 (HHS
Reference No. E–015–1995/2–US–02);
U.S. Patent Application 10/238,147 filed
09 Sep 2002 (HHS Reference No. E–
304–2003/0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact:
NIHOTT@mail.nih.gov; 301/496–7057.
E:\FR\FM\07SEN1.SGM
07SEN1
52804
Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices
Dated: August 29, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–14753 Filed 9–6–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
rwilkins on PROD1PC63 with NOTICES
Oligo Microarray for Detection of All
Known Mammalian and Avian
Pathogenic Viruses
Description of Technology: The
spectrum of pathogenic viruses of
importance in human disease,
agriculture and biology is not only large
and diverse, but continually evolving.
The identification or isolation of viral
pathogens, in correlation with the
presence of specific disease phenotypes,
is of paramount importance both to
diagnosis of disease and the subsequent
management or treatment of viral
infection. The limitations of current
viral detection methods, such as PCR
and immunoassays, led to the
development of a novel microarray
system for specific detection of viruses.
The technology offered here for
licensing provides a method for highthroughput screening of known
pathogenic viruses along with
VerDate Aug<31>2005
18:11 Sep 06, 2006
Jkt 208001
identification of ‘‘new’’ diseaseassociated viruses.
The novel method is based on a viral
microarray containing 10,000
immobilized DNA oligonucleotide
features, representing all known
mammalian and avian pathogenic
viruses (approximately 600). Software
was also developed to analyze the viral
microarray results. The oligonucleotide
features in this system are 60-mer long
and distributed across both conserved
and non-conserved regions of known
viral sequences. This design serves the
dual purpose of: (1) Facilitating
validation via redundant signals
associated with each represented virus
and (2) allowing for the discovery of
new viruses, which arise due to
recombination. In addition, positive and
negative controls against human and
mouse housekeeping genes are included
along with software for analysis of virus
microarray results.
Further advantages of the viral
microarray include: (a) The use of
sample inputs as little as 10ng of either
total DNA or RNA extracted from virus
infected cells, representing as few as 20
viral particles; (b) detection of viruses of
both DNA and RNA classes; (c) a
capacity for high-throughput screening
of various sample types including
serum, saliva and biopsy tissues; and (d)
analysis of a large number of samples in
parallel on identical arrays.
The detection of viral DNA is unique
to this technology, as other available
technologies only detect viral genomic
RNA or viral mRNA transcripts.
Additionally, the viral chip was found
to be highly specific and sensitive for
detecting different viral genomic
sequences in cell lines and multiple
viral constructs co-infection in cultured
cells.
Applications: (1) Detection and
identification of viruses that cause
disease; (2) Efficient discovery of new
pathogenic viruses; (3) Diagnosis of
human and animal disease outbreaks;
(4) Identification of viral agents used in
bioterrorism.
Development Status: (1) The preclinical performance of the viral
microarray was evaluated by application
of four virally positive infected cell
lines (JSC–1-harboring EBV and KSHV,
BCBL–1 harboring KSHV, HeLaharboring HPV18, Cem X 174 harboring
SIV). (2) Clinical performance was
tested and validated through analysis of
total RNA from cold (swab), Japanese
Encephalitis, Dengue, Ebola and West
Nile virus samples.
Inventors: Cassio S. Baptista (NCI),
Xiaolin Wu (NCI), David J. Munroe
(NCI).
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Patent Status: U.S. Provisional
Application No 60/797,334 filed 02 May
2006 (HHS Reference No. E–206–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, PhD, MBA; 301/
435–4507; thalhamc@mail.nih.gov
Collaborative Research Opportunity:
The NCI-Laboratory of Molecular
Technology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this oligo microarray for
identification and detection of all
known mammalian and avian
pathogenic viruses. Please contact Betty
Tong, PhD at 301–594–4263 or
tongb@mail.nih.gov for more
information.
Novel Monoclonal Antibody
Microarray
Description of Technology: Gene
expression profiling at the mRNA level
has proven to be a powerful and useful
tool, however this approach suffers from
inherent limitations: (1) The mRNA
abundance does not typically correlate
well with protein abundance and (2)
protein structure, activity, and function
can be altered and regulated by posttranslational modifications. Thus, there
is growing recognition that these
approaches should be complemented by
profiles of the gene products or proteins
themselves. The present invention
provides methods for constructing and
using a novel Monoclonal Antibody
Microarray which allows highthroughput determination of protein
expression profiles from serum, tissue,
and cultured cells.
The Monoclonal Antibody Microarray
consists of more than 1000 different
antibodies immobilized on a glass slide,
which recognize antigens from several
groups of proteins, including cytokines,
kinases, apoptotic proteins, growth
factor receptors, tumor suppressors, and
oncoproteins. Protein samples to be
identified and quantified are labeled
with fluorescence and hybridized to the
antibodies immobilized on the arrays.
By differentially labeling two protein
samples (dual-color labeling) and cohybridizing to the same microarray, a
direct comparative analysis of protein
expression can be performed using as
little as 100 µg of total protein. This
method allows a large number of
samples to be screened in parallel on
identical arrays.
Applications: (1) High-throughput
analysis of protein expression; (2) Direct
measurement of protein expression at
E:\FR\FM\07SEN1.SGM
07SEN1
]]>Agencies
[Federal Register Volume 71, Number 173 (Thursday, September 7, 2006)]
[Notices]
[Pages 52802-52804]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14753]
[[Page 52802]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Differential Expression of Molecules Associated With Intra-Cerebral
Hemorrhage
Description of Technology: Stroke affects 15 million people
worldwide each year, and is the number three leading cause of morbidity
in the United States. Although most forms of stroke are ischemic in
nature, approximately 10-15% of strokes are hemorrhagic. At present,
clinical applications for distinguishing between these two forms of
stroke do not exist.
The present invention describes a highly predictive, cost-effective
diagnostic assay capable of detecting whether an individual has
suffered from an intracerebral hemorrhagic stroke and the likelihood of
neurological recovery. It comprises a rapid screening device for
measuring differential expression patterns of nucleic acid molecules or
proteins of at least four hemorrhagic stroke-related genes. Accurate
prediction of hemorrhagic stroke will improve rapid diagnosis and aid
in determining early treatment regimens.
Applications:
1. Gene expression profile assay for determining hemorrhagic stroke
victims.
2. Means of differentiating between hemorrhagic stroke and ischemic
stroke thereby optimizing patient response to stroke therapies.
Market:
1. Annually, fifteen billion people suffer from strokes worldwide,
and an estimated 700,000 individuals have first-time or recurrent
strokes each year in the United States alone.
2. Almost three-fourth of all strokes occur in individuals over 65
years of age.
3. In 2006, the projected indirect and direct costs of stroke are
$57.9 billion.
Development Status: This technology requires clinical validation
studies.
Inventors: Alison Baird (NINDS) et al.
Patent Status: U.S. Provisional Application No. 60/807,027 filed 11
Jul 2006 (HHS Reference No. E-197-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Fatima Sayyid, M.H.P.M.; 301/435-4521;
sayyidf@mail.nih.gov.
Collaborative Research Opportunity: NINDS is also seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
this assay for determining hemorrhagic stroke victims. For additional
information, please contact: Heather Gunas, J.D., M.P.H; NINDS c/o NCI
TTB; 6120 Executive Blvd., Suite 450, Rockville, MD 20852; Phone: 301-
451-3944; Fax: 301-402-2117; E-mail: gunash@mail.nih.gov.
Diagnosis and Prognosis of Fabry Disease by Detecting Neuronal
Apoptosis Inhibitor Protein (NAIP) Expression
Description of Technology: Fabry disease is a severe metabolic
disorder that affects the vascular system of multiple tissues and
organs. An estimated 1 in 40,000 individuals inherit this rare disease,
and suffer from various complications including stroke, renal failure,
and cardiac arrest. At present, molecular markers that directly measure
cellular dysfunction to not exist, thus, prognosis for Fabry disease
therapy can not be assessed.
Available for licensing and commercial development is a rapid
diagnostic assay to identify individuals with Fabry disease and an
effective mechanism of evaluating enzyme replacement therapy. It
provides a quick, inexpensive device for determining expression
patterns of the neuronal apoptosis inhibitor protein (NAIP). Peripheral
blood white cells of Fabry disease patients are analyzed for elevated
levels of the marker NAIP, which is over-expressed in patients
suffering from acute strokes. These elevated levels have been found in
children with Fabry disease and point to the need for preventive
therapies. Additionally, this test can be routinely utilized for
evaluation of specific and non-specific therapies that aid in
minimizing the complications associated with Fabry disease.
Applications:
1. Rapid diagnostic test to identify person at risk for Fabry
disease.
2. Reliable diagnostic test to identify subject response to Fabry
disease therapy.
Market: Individuals genetically susceptible to Fabry disease.
Development Status: This technology requires analytic validation.
Inventors: Raphael Schiffmann (NINDS) et al.
Related Publications:
1. DF Moore, H Li, N Jeffries, V Wright, RA Cooper Jr, A Elkahloun,
MP Gelderman, E Zudaire, G Blevins, H Yu, E Goldin, AE Baird. Using
peripheral blood mononuclear cells to determine a gene expression
profile of acute ischemic stroke: a pilot investigation. Circulation.
2005 Jan 18; 111(2):212-221.
2. Y Okada, H Sakai, E Kohiki, E Suga, Y Yanagisawa, K Tanaka, S
Hadano, H Osuga, JE Ikeda. A dopamine D4 receptor antagonist attenuates
ischemia-induced neuronal cell damage via upregulation of neuronal
apoptosis inhibitory protein. J Cereb Blood Flow Metab. 2005 Jul;
25(7):794-806.
3. N Inohara, M Chamaillard, C McDonald, G Nu[ntilde]ez. NOD-LRR
proteins: role in host-microbial interactions and inflammatory disease.
Annu Rev Biochem. 2005 Jul; 74:355-383.
Patent Status: U.S. Provisional Application No. 60/806,295 filed 30
Jun 2006 (HHS Reference No. E-196-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Fatima Sayyid, M.H.P.M.; 301/435-4521;
sayyidf@mail.nih.gov.
Novel Treatment of Vascular Cognitive Impairment
Description of Technology: Available for licensing are methods and
formulations for treating or preventing Vascular Cognitive Impairment
(VCI) through mucosal administration of E-selectin, an inducible
adhesion molecule on endothelial cells. Vascular dementia is defined as
the loss of cognitive function resulting from ischemic, ischemic-
hypoxic, or hemorrhagic brain lesions as a result of cerebrovascular
diseases and pathologic
[[Page 52803]]
changes. Presently no adequate medical treatment exists for VCI.
Cerebrovascular disease causes proinflammatory cytokines such as
IL-1 and TNF to induce the expression of E-selectin on human
endothelium. E-selectin mediates the adhesion of various leukocytes,
including neutrophils, monocytes, eosinophils, natural killer cells,
and a subset of T cells to the activated endothelium. Activation of
vascular endothelial cells by proinflammatory cytokines is believed to
be involved in conversion of the luminal surface of endothelium from
anticoagulant and anti-inflammatory to procoagulant and pro-
inflammatory. These vascular changes are thought to underlie the
development of VCI.
Mucosally administered antigens can inhibit immune responses in an
antigen specific fashion by inducing a subset of lymphocytes to produce
anti-inflammatory cytokines in the presence of the antigen. This type
of tolerance has been termed ``bystander suppression''. In an animal
model of VCI, intranasal administered E-selectin suppressed activation
of vessel segments beginning to express E-selectin and thus prevented
the development of VCI. Immunosuppression via antigen-specific
modulation of the immune response (mucosal tolerance) should have no
systemic immunosuppressive effects.
Inventors: John M. Hallenbeck et al. (NINDS).
Patent Status: U.S. Provisional Application No. 60/712,359 filed 30
Aug 2005 (HHS Reference No. E-271-2005/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Norbert Pontzer, Ph.D., J.D.; 301/435-5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity: The NINDS Stroke Branch is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
the use of E-selectin for treatment of VCI. For more information,
please contact: Laurie Arrants, NINDS Technology Transfer Office, 301-
435-3112; arrantsl@ninds.nih.gov.
Use of LCAT To Reduce Cholesterol and Prevent Atherosclerosis
Description of Technology: Available for licensing and commercial
development is a method of decreasing accumulation of cholesterol in
arteries of humans by administering lecithin-cholesterol
acyltransferase (LCAT). This method is useful for the therapeutic
treatment of subjects at risk for developing atherosclerosis.
High plasma concentration of HDL cholesterol is associated with
reduced risk of cardiovascular diseases (such as ischemic stroke and
myocardial infarction). In contrast, low levels of HDL are associated
with increased risk of atherosclerotic diseases. The plasma protein
enzyme LCAT plays a critical role in the metabolism of HDL and it
facilitates the removal of cholesterol from the body. Individuals with
a mutation in the LCAT gene have low HDL plasma levels and exhibit an
increased risk for atherosclerosis.
Therefore, upregulation of LCAT function has been proposed as an
HDL-C increasing therapy, and may have atheroprotective effects. This
invention provides for several methods of administering LCAT
polypeptide to decrease cholesterol accumulation in arteries.
Development Status: Animal data available.
Inventors: Silvia Santamarina-Fojo, Jeffrey M. Hoeg, H. Bryan
Brewer (NHLBI).
Relevant Publication: JM Hoeg et al. Overexpression of
lecithin:cholesterol acyltransferase in transgenic rabbits prevents
diet-induced atherosclerosis. Proc Natl Acad Sci USA. 1996 Oct
15;93(21):11448-11453.
Patent Status: U.S. Patent No. 6,635,641 issued on 21 Oct 2003 (HHS
Reference No. E-007-1996/0-US-03); PCT Application No. PCT/US96/18159
filed 09 Sep 1996, which was published as WO 1997/17434 on 15 May 1997
(HHS Reference No. E-007-1996/0-PCT-02); Australian Patent No. 728257
issued on 19 Apr 2001; and National Stage filings in Canada and Europe.
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: NIHOTT@mail.nih.gov; 301/496-7057.
Devices for Aseptic Lyophilization of Biological Samples
Description of Technology: Biological materials are often
lyophilized and stored in small aliquots for long-term preservation as
a means of improving stability and expanding shelf life. At present,
sterility of solutions cannot be preserved throughout the
lyophilization process, and reconstituted samples must be filtered to
remove contaminants such as fungi or bacteria, resulting in
considerable loss of expensive sample via absorption by the filter.
Thus, there exists a need for a device that eliminates microbial
contamination throughout the lyophilization process and provides
materials that are ready to use following lyophilization.
This technology offers a functional method to prevent microbial
contamination during lyophilization and a simple means to prevent
contamination. It affords a convenient system for gas venting and
exchange utilizing a microcentrifuge tube fitted with a cap
incorporating a filter membrane. In a related technology, a unique,
cost-effective multi-well plate assembly provides for simultaneous
lyophilization of small sample volumes for high-throughput operations.
Thus, these technologies are well-suited for researchers concerned
about contamination during the lyophilization process. Given the
spillage often occurring within centrifugal freeze-dryers, these
technologies are also useful even when sterility is not needed, as they
prevent contamination from the often-dirty interiors of laboratory
centrifugal freeze-dryers, as well as cross-contamination between
samples undergoing lyophilization. In addition, by extending shelf-
lives, these technologies enable researchers to purchase expensive
biomolecules and pharmaceuticals in money-saving bulk quantities.
Furthermore, these technologies permit cells to be grown and stored
axenically, in small quantities, with or without lyophilization.
Applications:
1. Maximizes the shelf-lives of expensive biomolecules and
pharmaceuticals.
2. Makes practical the bulk purchase of expensive biomolecules and
pharmaceuticals by extending shelf-lives.
3. Makes possible the axenic storage of cells via aseptic freeze-
drying.
4. Makes possible the production and use of small, sterile aliquots
of precious materials by eliminating unnecessary filtration steps.
5. Makes possible the sterile growth of cells in small volumes.
Market:
1. Researchers worldwide who utilize sterile, labile compounds.
2. Researchers who utilize microbial, plant, or animal cell
cultures.
Development Status: Development is complete and invention has been
successfully tested.
Inventors: Geoffrey Kidd (NCI).
Patent Status: U.S. Patent 5,958,778 issued 28 Sep 1999 (HHS
Reference No. E-015-1995/2-US-01); U.S. Patent 6,503,455 issued 07 Jan
2003 (HHS Reference No. E-015-1995/2-US-02); U.S. Patent Application
10/238,147 filed 09 Sep 2002 (HHS Reference No. E-304-2003/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: NIHOTT@mail.nih.gov; 301/496-7057.
[[Page 52804]]
Dated: August 29, 2006.
Steven M. Ferguson,
Director,Division of Technology Development and Transfer,Office of
Technology Transfer,National Institutes of Health.
[FR Doc. E6-14753 Filed 9-6-06; 8:45 am]
BILLING CODE 4140-01-P
